Inhibitors of APOL1 and methods of using same

US12060346B2 · kind B2 · utility

Assignee

• Vertex Pharmaceuticals Incorporated · US

Inventors

• Jingrong Cao · Newton, US
• Jon Come · Cambridge, US
• Leslie Dakin · Waltham, US
• Francois Denis · Saint Lazare, CA
• Warren Dorsch · Boston, US
• Anne Fortier · Rockville, US
• Martine Hamel · Boston, US
• Elaine B. Krueger · Cambridge, US
• Brian Ledford · Attleboro, US
• Suganthini S. Nanthakumar · Newton, US
• Olivier Nicolas · Winston-Salem, US
• Camil SAYEGH · Belmont, US
• Timothy J. Senter · Arlington, US
• Tiansheng Wang · Concord, US
• Michael Aaron Brodney · East Lyme, US
• Kan-Nian Hu · Watertown, US
• Peter Jamison Rose · Littleton, US
• Kevin James GAGNON · Acton, US
• Yi-Qun Shi · East Brunswick Township, US
• Muna Shrestha · Belmont, US
• Ales Medek · Winchester, US
• Faith WITKOS · Attleboro, US

Key dates

• Filing date: Feb 7, 2023
• Grant date: Aug 13, 2024
• Expiry date: Feb 7, 2043

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07B2200/13
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The disclosure provides at least one entity chosen from compounds of formula (I), solid state forms of the same, compositions comprising the same, and methods of using the same, including use in treating focal segmental glomerulosclerosis (FSGS) and/or non-diabetic kidney disease (NDKD).